Research programme: antimalarials - Medicines for Malaria Venture/Takeda/University of Melbourne

Drug Profile

Research programme: antimalarials - Medicines for Malaria Venture/Takeda/University of Melbourne

Alternative Names: ELQ-300

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Medicines for Malaria Venture
  • Developer Medicines for Malaria Venture; Takeda; University of Melbourne
  • Class Ethers; Quinolones; Small molecules
  • Mechanism of Action Electron transport complex III inhibitors; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Malaria

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Malaria(Prevention) in Japan (PO)
  • 04 Nov 2015 Medicines for Malaria Venture, Takeda and the University of Melbourne receive grant from Global Health Innovative Technology Fund for development of proteasome inhibitors in Malaria
  • 07 Nov 2013 Medicines for Malaria Venture and Takeda receive grant from Global Health Innovative Technology Fund for ELQ 300 development in Malaria
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top